antibody

Proprotein convertase subtilisin/kexin type 9 (PCSK9), NARC1 BLOCKING EPITOPE

MBS395898

0.1 mg

315 USD

polyclonal

rabbit

nonconjugated

western blot, ELISA, enzyme immunoassay

Antibody

Proprotein convertase subtilisin/kexin type 9 (PCSK9), NARC1 BLOCKING EPITOPE

Proprotein convertase subtilisin/kexin type 9 (PCSK9), NARC1 BLOCKING EPITOPE

Proprotein convertase PC9; Subtilisin/kexin-like protease PC9; Neural apoptosis-regulated convertase 1

proprotein convertase subtilisin/kexin type 9 preproprotein; Proprotein convertase subtilisin/kexin type 9; proprotein convertase subtilisin/kexin type 9; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; convertase subtilisin/kexin type 9 preproprotein; proprotein convertase subtilisin/kexin type 9; Neural apoptosis-regulated convertase 1; NARC-1; Proprotein convertase 9; PC9; Subtilisin/kexin-like protease PC9

PCSK9

PCSK9; PCSK9; FH3; PC9; NARC1; LDLCQ1; NARC-1; HCHOLA3; NARC1; NARC-1; PC9

PCSK9_HUMAN

Polyclonal

IgG

Rabbit

Human

692

Affinity Immunoaffinity Purification.

Provided as solution in phosphate buffered saline with 0.08% sodium azide

0.35mg/ml

Product should be stored at -20 degree C. Aliquot to avoid freeze/thaw cycles

Western Blot (WB), Functional epitope reported to block PCSK9-LDLR interaction, ELISA (EIA)

Antibody can be used for Western Blotting (1:400 dilution) and immunocytochemistry (2ug/ml). Optimal concentration should be evaluated by serial dilutions.

Immunogen: Synthetic peptide derived from the human PCSK9 protein reported to block PCSK9-LDLR interaction.

Positive Control: Expressed in neuro-epithelioma, colon carcinoma, hepatic and pancreatic cell lines, and in Schwann cells.

Antigen Immunoaffinity Purified Polyclonal; Lipid Mediators

This anitbody is made to an epitope that is reported to block the PCSK9?LDLR (low density lipoprotein receptor) interaction. PCSK9 binds to the EGF-A domain of the LDLR and signals LDLR degradation. Reduced LDLR levels result in decreased LDL (low density lipid) metabolism leading to hypercholesterolemia.

31317307

NP_777596.2

NM_174936.3

Q8NBP7

73 kDa

This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3). [provided by RefSeq, Jul 2008]

Function: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na+ channel (ENaC)-mediated Na+ absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. Ref.12 Ref.13 Ref.14 Ref.16 Ref.19 Ref.23 Ref.31. Cofactor: Calcium . Probable. Enzyme regulation: Its proteolytic activity is autoinhibited by the non-covalent binding of the propeptide to the catalytic domain. Inhibited by EGTA. Subunit structure: Monomer. Can self-associate to form dimers and higher multimers which may have increased LDLR degrading activity. The precursor protein but not the mature protein may form multimers. Interacts with APOB, VLDLR, LRP8/APOER2 and BACE1. The full length immature form (pro-PCSK9) interacts with SCNN1A, SCNN1B and SCNN1G. The pro-PCSK9 form (via C-terminal domain) interacts with LDLR. Ref.12 Ref.13 Ref.14 Ref.16 Ref.20 Ref.23 Ref.31. Subcellular location: Cytoplasm. Secreted. Endosome. Lysosome. Cell surface. Endoplasmic reticulum. Golgi apparatus. Note: Autocatalytic cleavage is required to transport it from the endoplasmic reticulum to the Golgi apparatus and for the secretion of the mature protein. Localizes to the endoplasmic reticulum in the absence of LDLR and co-localizes to the cell surface and to the endosomes/lysosomes in the presence of LDLR. The sorting to the cell surface and endosomes is required in order to fully promote LDLR degradation. Ref.12 Ref.16 Ref.23. Tissue specificity: Expressed in neuro-epithelioma, colon carcinoma, hepatic and pancreatic cell lines, and in Schwann cells. Domain: The C-terminal domain (CRD) is essential for the LDLR-binding and degrading activities (Ref.21). Ref.21The catalytic domain is responsible for mediating its self-association. Ref.21. Post-translational modification: Cleavage by furin and PCSK5 generates a truncated inactive protein that is unable to induce LDLR degradation.Undergoes autocatalytic cleavage in the endoplasmic reticulum to release the propeptide from the N-terminus and the cleavage of the propeptide is strictly required for its maturation and activation. The cleaved propeptide however remains associated with the catalytic domain through non-covalent interactions, preventing potential substrates from accessing its active site. As a result, it is secreted from cells as a propeptide-containing, enzymatically inactive protein. Ref.9 Ref.11Phosphorylation protects the propeptide against proteolysis. Polymorphism: Variant Leu-23 ins polymorphism in PCSK9 might have a modifier effect on LDLR mutation and familial hypercholesterolemia.Genetic variations in PCSK9 define the low density lipoprotein cholesterol level quantitative trait locus 1 (LDLCQ1) [. MIM:603776]. Involvement in disease: Hypercholesterolemia, autosomal dominant, 3 (HCHOLA3) [MIM:603776]: A familial condition characterized by elevated circulating cholesterol contained in either low-density lipoproteins alone or also in very-low-density lipoproteins.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.33. Sequence similarities: Belongs to the peptidase S8 family.Contains 1 peptidase S8 domain. Sequence caution: The sequence BAC11572.1 differs from that shown. Reason: Frameshift at position 494.

0.1 mg

315 USD